With a deep­er dis­count in place, NICE now ready to en­dorse use of No­var­tis' Kym­ri­ah in adult lym­phoma pa­tients

Looks like No­var­tis has made nice with UK’s NICE. The cost-ef­fec­tive­ness watch­dog re­versed its Sep­tem­ber po­si­tion to en­dorse the Swiss drug­mak­er’s CAR-T ther­a­py, Kym­ri­ah, in adult lym­phoma pa­tients, af­ter ac­cept­ing a deep­er dis­count on a ther­a­py that car­ries a list price of £282,000 (rough­ly $368232), it said on Fri­day.

Kym­ri­ah was the first CAR-T drug to win ap­proval in the Unit­ed States and Eu­rope, but sales have suf­fered due to man­u­fac­tur­ing wob­bles. Still, the com­pa­ny ex­pects the drug — which reengi­neers a pa­tient’s’ im­mune cells to rec­og­nize and at­tack can­cer — to even­tu­al­ly gen­er­ate block­buster sales.

NICE, in a draft re­view in Sep­tem­ber, said al­though the treat­ment has sig­nif­i­cant clin­i­cal ben­e­fit, No­var­tis has not pro­vid­ed any da­ta com­par­ing its use to that of last-re­sort chemother­a­py, the stan­dard of care in the pa­tient pop­u­la­tion. It al­so said the im­munother­a­py was far too ex­pen­sive to rec­om­mend for use in adults with lym­phoma, but sep­a­rate­ly en­dorsed its use in leukemia pa­tients up to the age of 25. On Thurs­day, the BBC re­port­ed that an 11-year-old boy with leukemia was the first NHS pa­tient to be giv­en Kym­ri­ah, af­ter pri­or treat­ment failed to keep his can­cer at bay.

On Fri­day, NICE said adult lym­phoma pa­tients would be able to gain ac­cess to the drug via the Can­cer Drugs Fund — a fund that aims to make promis­ing can­cer drugs avail­able to pa­tients be­fore they are ful­ly sanc­tioned for use in the NHS. “CAR T-cell ther­a­py is ex­pen­sive, how­ev­er the treat­ment is spe­cif­ic to each in­di­vid­ual and could be a po­ten­tial cure for some, al­though it is ear­ly days. Our rec­om­men­da­tion for…the Can­cer Drugs Fund means peo­ple can ben­e­fit while more da­ta is col­lect­ed,” the agency said in a state­ment.

No­var­tis’ re­cent en­gage­ment with NICE has not been smooth-sail­ing. Last month, NICE re­fused to en­dorse No­var­tis’ mi­graine-pre­ven­tion treat­ment Aimovig, say­ing the to­tal­i­ty of the da­ta sup­port­ing the med­i­cine did not in­clude all “rel­e­vant” com­par­isons against ex­ist­ing drugs and out­comes. The com­pa­ny is work­ing with the agency to see whether that de­ter­mi­na­tion can be changed, but more im­por­tant­ly, it will be hop­ing to stay on good terms with agency ahead of the ex­pect­ed ap­proval of its SMA gene-ther­a­py, Zol­gens­ma. If ap­proved, the drug­mak­er thinks it would be jus­ti­fied in charg­ing be­tween $4 mil­lion to $5 mil­lion for the ther­a­py, a price that will all but cer­tain in­spire crit­i­cism from NICE.

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jackie Fouse, Agios CEO

Agios scores its sec­ond pos­i­tive round of da­ta for its lead pipeline drug — but that won't an­swer the stub­born ques­tions that sur­round this pro­gram

Agios $AGIO bet the farm on its PKR activator drug mitapivat when it recently decided to sell off its pioneering cancer drug Tibsovo and go back to being a development-stage company — for what CEO Jackie Fouse hoped would be a short stretch before they got back into commercialization.

On Tuesday evening, the bellwether biotech flashed more positive topline data — this time from a small group of patients in a single-arm study. And the executive team plans to package this with its earlier positive results from a controlled study to make its case for a quick OK.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (L) and Len Schleifer (Regeneron)

Re­gen­eron touts pos­i­tive pre­lim­i­nary im­pact of its Covid an­ti­body cock­tail, pre­vent­ing symp­to­matic in­fec­tions in high-risk group

Regeneron flipped its cards on an interim analysis of the data being collected for its Covid-19 antibody cocktail used as a safeguard against exposure to the virus. And the results are distinctly positive.

The big biotech reported Tuesday morning that their casirivimab and imdevimab combo prevented any symptomatic infections from occurring in a group of 186 people exposed to the virus through a family connection, while the placebo arm saw 8 of 223 people experience symptomatic infection. Symptomatic combined with asymptomatic infections occurred in 23 people among the 223 placebo patients compared to 10 of the 186 subjects in the cocktail arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

As­traZeneca scores new goal on the pipeline front, adding its first AI-gen­er­at­ed tar­get to the port­fo­lio

As more and more biopharmas develop artificial intelligence platforms, the drug discovery process is being reshaped to fit new goals on cutting down the prodigious amount of time, energy and money that go into a drug program. Now one of the most ambitious players in the drive to improve on ROI, AstraZeneca, is marking a milestone on that front by adding the first target generated by AI to its portfolio.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.